- Home
- CLRB vs KZIA Comparison
CLRB vs KZIA Comparison
Compare CLRB & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRB
- KZIA
- Stock Information
- Founded
- CLRB 2002
- KZIA 1994
- Country
- CLRB United States
- KZIA Australia
- Employees
- CLRB N/A
- KZIA N/A
- Industry
- CLRB Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- CLRB Health Care
- KZIA Health Care
- Exchange
- CLRB Nasdaq
- KZIA Nasdaq
- Market Cap
- CLRB 12.8M
- KZIA 11.7M
- IPO Year
- CLRB N/A
- KZIA 1999
- Fundamental
- Price
- CLRB $3.36
- KZIA $7.60
- Analyst Decision
- CLRB Hold
- KZIA Strong Buy
- Analyst Count
- CLRB 2
- KZIA 3
- Target Price
- CLRB N/A
- KZIA $16.00
- AVG Volume (30 Days)
- CLRB 321.2K
- KZIA 76.4K
- Earning Date
- CLRB 10-31-2025
- KZIA 12-26-2025
- Dividend Yield
- CLRB N/A
- KZIA N/A
- EPS Growth
- CLRB N/A
- KZIA N/A
- EPS
- CLRB N/A
- KZIA N/A
- Revenue
- CLRB N/A
- KZIA $1,549,158.00
- Revenue This Year
- CLRB N/A
- KZIA N/A
- Revenue Next Year
- CLRB N/A
- KZIA N/A
- P/E Ratio
- CLRB N/A
- KZIA N/A
- Revenue Growth
- CLRB N/A
- KZIA 248983.08
- 52 Week Low
- CLRB $3.17
- KZIA $2.86
- 52 Week High
- CLRB $66.00
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- CLRB 32.40
- KZIA 54.14
- Support Level
- CLRB $3.70
- KZIA $6.51
- Resistance Level
- CLRB $4.10
- KZIA $8.02
- Average True Range (ATR)
- CLRB 0.32
- KZIA 0.45
- MACD
- CLRB -0.08
- KZIA 0.10
- Stochastic Oscillator
- CLRB 9.69
- KZIA 69.21
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.